Cargando…

Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women

Chemotherapy and endocrine therapies are mainstays of treatment for early and advanced hormone receptor-positive (HR+) breast cancer. In premenopausal women with HR+ tumors, the benefits of adding ovarian function suppression (OFS) to endocrine therapy have been debated. Consequently, for many years...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Yen-Shen, Wong, Andrea, Kim, Hee-Jeong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477635/ https://www.ncbi.nlm.nih.gov/pubmed/34595110 http://dx.doi.org/10.3389/fonc.2021.700722

Ejemplares similares

Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
por: Jonat, W.
Publicado: (1998)

Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer
por: Kojima, Nobue, et al.
Publicado: (2018)

Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists
por: Spicer, Darcy V, et al.
Publicado: (2000)

Meningiomas in Premenopausal Women: Role of the Hormone Related Conditions
por: Maiuri, Francesco, et al.
Publicado: (2020)

Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
por: Nicholson, R. I., et al.
Publicado: (1979)

Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review
por: Zhang, Xianlu, et al.
Publicado: (2023)

Progression of Intracranial Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer: Case Report
por: ANDA, Takeo, et al.
Publicado: (2014)

Luteinizing Hormone-Releasing Hormone Distribution in the Anterior Hypothalamus of the Female Rats
por: Castañeyra-Ruiz, Leandro, et al.
Publicado: (2013)

Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor?Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors
por: Suh, Koung Jin, et al.
Publicado: (2017)

Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome
por: Chun, Sungwook
Publicado: (2014)

Scheduled simple production method of pseudopregnant female mice for embryo transfer using the luteinizing hormone-releasing hormone agonist
por: Sari, Gema Puspa, et al.
Publicado: (2022)

Analysis of the benefit of gonadotropin-releasing hormone agonist treatment in premenopausal women undergoing hematopoietic cell transplantation
por: Han, Ruxue, et al.
Publicado: (2023)

Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women
por: Bernhardt, Sarah M., et al.
Publicado: (2016)

Effects of a luteinizing hormone-releasing hormone agonist on cognitive, sexual, and hormonal functions in patients with prostate cancer: relationship with testicular and adrenal androgen levels
por: Okamoto, Kohei, et al.
Publicado: (2015)

Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment
por: Ichaoui, Hamza, et al.
Publicado: (2019)

Diminished Ovarian Reserve Predisposes to Premature Luteinizing Hormone Surges in Gonadotropin-Releasing Hormone Antagonist Cycles in In vitro Fertilization
por: Kochhar, Puneet Kaur, et al.
Publicado: (2020)

The enigma of the gonadotropin-releasing hormone pulse frequency governing individual secretion of luteinizing hormone and follicle-stimulating hormone
por: Lambalk, Cornelis B.
Publicado: (2023)

Topographical localization of the receptors for luteinizing hormone- releasing hormone on the surface of dissociated pituitary cells
Publicado: (1977)

Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis
por: Shen, Yan-Wei, et al.
Publicado: (2015)

Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report
por: Chang, John I-Chiang, et al.
Publicado: (2016)

Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer
por: Koh, Yoko, et al.
Publicado: (2020)

Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer: A network meta-analysis
por: Jiang, Mengjie, et al.
Publicado: (2021)

Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials.
por: Kaufmann, M.
Publicado: (1998)

Expression of the luteinizing hormone receptor (LHR) in ovarian cancer
por: Xiong, Shigang, et al.
Publicado: (2019)

The serum follicle stimulating hormone-to-luteinizing hormone ratios can predict assisted reproductive technology outcomes in women undergoing gonadotropin releasing hormone antagonist protocol
por: Zhao, Shen, et al.
Publicado: (2023)

Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome
por: Liu, Nana, et al.
Publicado: (2012)

Characterization of Luteinizing Hormone and Luteinizing Hormone Receptor and Their Indispensable Role in the Ovulatory Process of the Medaka
por: Ogiwara, Katsueki, et al.
Publicado: (2013)

Concurrent Gonadotropin-Releasing Hormone Agonist Administration with Chemotherapy Improves Neoadjuvant Chemotherapy Responses in Young Premenopausal Breast Cancer Patients
por: Kim, Hee Jeong, et al.
Publicado: (2015)

Application of luteinizing hormone-releasing hormone–ferrosoferric oxide nanoparticles in targeted imaging of breast tumors
por: Nian, Di, et al.
Publicado: (2019)

Detection of urinary luteinizing hormone in Japanese black cows after administration of gonadotropin-releasing hormone
por: MIYAZAKI, Tamako, et al.
Publicado: (2021)

Effects of intravenous administration of neurokinin receptor subtype-selective agonists on gonadotropin-releasing hormone pulse generator activity and luteinizing hormone secretion in goats
por: YAMAMURA, Takashi, et al.
Publicado: (2014)

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
por: Shim, Myungsun, et al.
Publicado: (2019)

Effects of luteinizing hormone-releasing hormone and arginine-vasotocin on the sperm-release response of Günther's Toadlet, Pseudophryne guentheri
por: Silla, Aimee J
Publicado: (2010)

Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer
por: Qiu, Lin, et al.
Publicado: (2016)

Effects of growth hormone administration on luteinizing hormone secretion in healthy older men and women
por: Muniyappa, Ranganath, et al.
Publicado: (2017)

Gonadotropin-releasing hormone agonist protects ovarian function in young patients with ovarian malignancy undergoing platinum-based chemotherapy: A prospective study
por: Xie, Ya, et al.
Publicado: (2022)

Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?
por: Lambertini, Matteo, et al.
Publicado: (2019)

Cigarette Smoking and Effects on Hormone Function in Premenopausal Women
por: Windham, Gayle C., et al.
Publicado: (2005)

Adjuvant hormonal therapy in premenopausal women with breast cancer
por: Smyth, Lillian, et al.
Publicado: (2015)

Real-World Clinical Outcomes of Ribociclib in Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal HR+/HER2− Advanced Breast Cancer Patients: An Italian Managed Access Program
por: Staropoli, Nicoletta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3hm5mg31dbuj8bde59jbs44hr0